# Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference

- Link: https://www.thailand-business-news.com/pr-news/kazia-therapeutics-to-participate-in-fireside-chat-at-guggenheim-3rd-annual-healthcare-innovation-conference
- Published: 2026-10-29T18:00:00+07:00
- Author: PR Newswire

|   |

SYDNEY, Oct. 29, 2026 /PRNewswire/ — [Kazia Therapeutics Limited](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4809291-1&h=1734281094&u=https%3A%2F%2Fwww.kaziatx.com%2F&a=Kazia+Therapeutics+Limited)(
NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that
selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment
resistance, today announced that John Friend, MD, Chief Executive Officer, and Jeffrey
Kraws, Head of Corporate Strategy & Development, will participate in a fireside 
chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, being held November
9 to 11, 2026, in Boston, Massachusetts.

**Conference Details**

**Event: **Guggenheim 3rd Annual Healthcare Innovation Conference
**Date: **Monday,
November 9, 2026**Time: **8:30 a.m. Eastern Standard Time (EST)**Presenters: **John
Friend, MD, Chief Executive Officer and Jeffrey Kraws, Head of Corporate Strategy&
Development**Format: **Fireside chatA live webcast of the fireside chat will be 
available [here](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4809291-1&h=1831542664&u=https%3A%2F%2Fevent.summitcast.com%2Fview%2FoVDtKqmPn2tPc7VV7WsLAC%2FGNut5UUoxstnuAr3JTCUuk&a=here).

Kazia management will also be available for one-on-one meetings during the conference.
Interested participants should contact their Guggenheim representative to arrange
a meeting.

**About Kazia Therapeutics Limited**

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused biotechnology company
developing therapies that selectively reprogram cancer biology, restore anti-tumor
immunity and overcome treatment resistance. Kazia’s lead asset, paxalisib, is an
investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across
multiple forms of cancer, including cancers of the central nervous system, advanced
breast cancer and colorectal cancer. Paxalisib has received U.S. FDA Fast Track 
and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered
brain metastases with radiation and Rare Pediatric Disease and Orphan Drug designations
for select pediatric brain tumors, including diffuse intrinsic pontine glioma and
atypical teratoid/rhabdoid tumor.

Kazia is also advancing two potentially first-in-class preclinical programs: NDL2,
a nuclear PD-L1 protein degrader targeting a newly identified mechanism of immunotherapy
resistance and metastatic progression, and MSETC, a SETDB1 inhibitor intended to
restore immune signaling in tumors that have become resistant to immunotherapy, 
including checkpoint inhibitors. Additionally, Kazia’s portfolio includes EVT801,
a small molecule VEGFR-3 inhibitor that the Company is exploring for potential partnering
opportunities.

For more information, visit [www.kaziatx.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4809291-1&h=4018627739&u=https%3A%2F%2Fwww.kaziatx.com%2F&a=www.kaziatx.com),
as well as follow us on [X](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4809291-1&h=1898250155&u=https%3A%2F%2Fx.com%2FKaziaTx&a=X)
and [LinkedIn](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4809291-1&h=807431851&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fkaziatx%2Fhome%2F&a=LinkedIn).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference ](http://www.prnasia.com/story/archive/5083904_AE83904_0?rand=184833)